Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy

Experimental Hematology

Volumn 35, Issue 7, 2007, Pages 1069-1073

  Otto Duessel, Maya ^a   Aguilar, Michelle ^a   Nick, Hanspeter ^b   Moats, Rex ^a   Wood, John C ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; IRON DEXTRAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE MODEL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GERBIL; IRON CARDIOMYOPATHY; IRON CHELATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TISSUE LEVEL;

ANIMALS; BENZOIC ACIDS; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERBILLINAE; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MYOCARDIUM; TRIAZOLES;

ANIMALIA; GERBILLINAE;

EID: 34250360747     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.04.001     Document Type: Article

References (12)

1. Borgna-Pignatti C., Rugolotto S., De Stefano P., et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 850 (1998) 227-231
2. Cohen A.R., Galanello R., Pennell D.J., Cunningham M.J., and Vichinsky E. Thalassemia. Hematology (Am Soc Hematol Educ Program) (2004) 14-34
3. Lerner N., Blei F., Bierman F., Johnson F., Johnson L., and Piomelli S. Chelation therapy and cardiac status in older patients with thalassemia major. Am J Pediatr Hematol Oncol 12 (1990) 56-60
4. Aldouri M.A., Wonke B., Hoffbrand A.V., et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 84 (1990) 113-117
5. Hershko C., Konijn A.M., Nick H.P., Breuer W., Cabantchik Z.I., and Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 97 (2001) 1115-1122
6. Wood J., Otto-Duessel M., Gonzalez I., et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res 148 (2006) 272-280
7. * in transfusion dependent anemias receiving ICL670 (deferasirox). Blood (ASH Annual Meeting Abstracts) 106 (2005) 3600
8. Wood J.C., Otto-Duessel M., Aguilar M., et al. Dose response of deferoxamine, deferiprone, and ICL670 chelation therapy in a gerbil model of iron overload. Blood 104 (2004) 985a
9. Weiss M., Fresneau M., Camenisch G.P., Kretz O., and Gross G. In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. Drug Metab Dispos 34 (2006) 971-975
10. Hershko C., et al. Iron chelation therapy. Curr Hematol Rep 4 (2005) 110-116
11. Nisbet-Brown E., Olivieri N.F., Giardina P.J., et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361 9369 (2003) 1597-1602
12. Galanello R., Piga A., Alberti D., Rouan M.C., Bigler H., and Sechaud R. Safety, tolerability pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 43 (2003) 565-572